Daratumumab Plus VRd Yields Sustained MRD-Negativity Regardless of Cytogenetic Risk Status in NDMM

Source: Pharmacy Times articles

Daratumumab combined with VRd significantly improved outcomes in transplant-ineligible/transplant deferred patients with newly diagnosed multiple myeloma.
Read More